Perfil
Mei Hui Li is currently the Vice Chairman & Chief Executive Officer at Cinemark Co. Ltd. She also holds positions as an Independent Director at CTCI Advanced Systems Inc., FOCI Fiber Optic Communications, Inc., and Director at Advagene Biopharma Co., Ltd. Ms. Li previously worked as the Managing Director at Taiwan Secom Co., Ltd. She graduated from National Taiwan University.
Cargos activos de Mei Hui Li
| Empresas | Cargo | Inicio |
|---|---|---|
| CTCI ADVANCED SYSTEMS INC. | Director/Miembro de la Junta | 26/06/2014 |
| FOCI FIBER OPTIC COMMUNICATIONS, INC. | Director/Miembro de la Junta | 06/06/2018 |
| ADVAGENE BIOPHARMA CO., LTD. | Director/Miembro de la Junta | - |
Cinemark Co. Ltd. | Director Ejecutivo | - |
Antiguos cargos conocidos de Mei Hui Li.
| Empresas | Cargo | Fin |
|---|---|---|
| TAIWAN SECOM CO., LTD. | Corporate Officer/Principal | - |
Formación de Mei Hui Li.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Taiwan Secom Co., Ltd.
Taiwan Secom Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Provides system security services | Commercial Services |
CTCI Advanced Systems Inc.
CTCI Advanced Systems Inc. Electrical ProductsProducer Manufacturing Manufactures control system software and hardware | Producer Manufacturing |
National Taiwan University
National Taiwan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FOCI Fiber Optic Communications, Inc.
FOCI Fiber Optic Communications, Inc. Electrical ProductsProducer Manufacturing Manufactures and sells fiber optic interconnectors | Producer Manufacturing |
Cinemark Co. Ltd. | |
Advagene Biopharma Co., Ltd.
Advagene Biopharma Co., Ltd. BiotechnologyHealth Technology Engages in the development of products such as nasal influenza vaccine, airway allergy immunotherapy and COVID-19 immunotherapy | Health Technology |
- Bolsa de valores
- Insiders
- Mei Hui Li
















